Earnings ·
Pfizer Inc. reported second-quarter 2026 revenues of $15.0 billion and an adjusted diluted EPS of $0.77, while…
PFEPfizer Inc
Pfizer Inc. reported second-quarter 2026 revenues of $15.0 billion and an adjusted diluted EPS of $0.77, while reporting a GAAP loss per share of $(0.04) due to $4.3 billion in non-cash intangible asset impairments. The company raised its full-year 2026 revenue guidance midpoint by $500 million to $61.5 billion and reaffirmed adjusted diluted EPS guidance of $2.80 to $3.00. Pfizer announced an expansion of productivity enhancement initiatives, targeting an additional $2.5 billion in net cost savings from 2027 through 2029. CFO Dave Denton is stepping down on August 15, with Cecile Guegan named Interim CFO effective August 16. The company also completed a strategic licensing agreement with Innovent Biologics for $650 million upfront plus up to $9.85 billion in milestones. Pfizer operates in the global biopharmaceutical industry, developing and commercializing prescription medicines, vaccines, and consumer health products.